Sanyou Biopharmaceutical and Guangzhou Baiyunshan Xihe Health Pharmaceutical have signed a strategic collaboration agreement to co-develop radiopharmaceutical and radiodiagnostic products by combining their expertise in artificial intelligence-driven drug discovery and nuclear medicine.

• Development Roles: Sanyou Bio will focus on AI-driven discovery and optimisation of antibodies and targeting molecules, while Baiyunshan Xihe will support radionuclide production, GMP manufacturing, radiolabelling and clinical translation.
• Research Scope: The collaboration aims to establish an integrated research and development framework spanning target molecule discovery through to clinical translation.
• Clinical Focus: The partnership is intended to support the development of radiopharmaceutical and radiodiagnostic products for precision oncology diagnosis and therapy.

This summary is based on a news article published by BioSpectrum Asia.

Image for illustrative purposes only. Source: Canva.

About Ehub365

For Corporate Clients, ehub365 division delivers critical insights into the ASEAN medical sector, covering investments, new services, and practitioner news. 

A member of 365Asia. Our additional group services are Health365, 365Asia, 健康365, 365Sehat, and 365MEC.